Results 81 to 90 of about 1,445 (106)

Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015. [PDF]

J Thromb Haemost, 2015
europepmc   +1 more source

Abstracts of the 2013 Annual Meeting of the American College of Rheumatology. October 25-30, 2013. San Diego, California, USA. [PDF]

Arthritis Rheum, 2013
europepmc   +1 more source

Mammalian gene studies. [PDF]

Curr Opin Biotechnol, 1993
europepmc   +1 more source

Pharmaceutical applications. [PDF]

Curr Opin Biotechnol, 1992
europepmc   +1 more source

CIP

Истраживања, 2012
- -
doaj  

Some of the next articles are maybe not open access.

Related searches:

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Investigational New Drugs, 2021
Jonathan Cohen, Ruth Perets, Ronnie Shapira-Frommer   +2 more
exaly  

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Investigational New Drugs, 2021
Samuel J Klempner, Danni Yu, Robert Wesolowski   +2 more
exaly  

Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses

International Journal of Radiation Oncology Biology Physics, 1994
Toru Shibata, Yuta Shibamoto, Natsuo Oya   +2 more
exaly  

In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation

International Journal of Radiation Oncology Biology Physics, 1991
Keisuke Sasai, Masato Fushiki, Sumio Suyama   +2 more
exaly